Analyzing Immunocore (NASDAQ:IMCR) and Cellectis (NASDAQ:CLLS)

Immunocore (NASDAQ:IMCR) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.

Volatility & Risk

Immunocore has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500.

Earnings and Valuation

This table compares Immunocore and Cellectis’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$265.27 million	7.09	-$55.29 million	($1.22)	-30.84
Cellectis	$13.03 million	8.70	-$101.06 million	($1.29)	-1.58

Immunocore has higher revenue and earnings than Cellectis. Immunocore is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 9.1% of Immunocore shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Immunocore and Cellectis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunocore	-22.60%	-16.54%	-8.75%
Cellectis	-529.81%	-67.41%	-20.83%

Analyst Ratings

This is a breakdown of recent recommendations for Immunocore and Cellectis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	0	1	12	0	2.92
Cellectis	0	0	2	0	3.00

Immunocore currently has a consensus price target of $81.00, suggesting a potential upside of 115.25%. Cellectis has a consensus price target of $8.00, suggesting a potential upside of 292.16%. Given Cellectis’ stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than Immunocore.

Summary

Immunocore beats Cellectis on 8 of the 14 factors compared between the two stocks.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.